Zdrowie i gospodarka · 03/11/1994

Financial Disclosure by Clinical Investigators; Correction

The Food and Drug Administration (FDA) is correcting a proposed rule that appeared in the Federal Register of September 22, 1994 (59 FR 48708). The document proposed to require that the sponsor of any drug, biological product, or device submit certain information concerning the compensation to, and financial interests of, any clinical investigator conducting clinical studies to determine whether that product meets the marketing requirements specified by the agency. The document was published with an error. This document corrects that error.